PT - JOURNAL ARTICLE AU - W. J. T. Bos AU - J.-P. Bertoglio AU - L. Gostiaux TI - Modeling the role of clusters and diffusion in the evolution of COVID-19 infections during lock-down AID - 10.1101/2020.07.22.20159830 DP - 2020 Jan 01 TA - medRxiv PG - 2020.07.22.20159830 4099 - http://medrxiv.org/content/early/2020/11/20/2020.07.22.20159830.short 4100 - http://medrxiv.org/content/early/2020/11/20/2020.07.22.20159830.full AB - Epidemics such as the spreading of the SARS-CoV-2 virus are highly non linear, and therefore difficult to predict. In the present pandemic as time evolves, it appears more and more clearly that a clustered dynamics is a key element of description. This means that the disease rapidly evolves within spatially localized networks, that diffuse and eventually create new clusters. We improve upon the simplest possible compartmental model, the SIR model, by adding an additional compartment associated with the clustered individuals. This sophistication is compatible with more advanced compartmental models and allows, at the lowest level of complexity, to leverage the well-mixedness assumption. The so-obtained SBIR model takes into account the effect of inhomogeneity on epidemic spreading, and compares satisfactorily with results on the pandemic propagation in a number of European countries, during and immediately after lock-down. Especially, the decay exponent of the number of new cases after the first peak of the epidemic is captured without the need to vary the coefficients of the model with time. We show that this decay exponent is directly determined by the diffusion of the ensemble of clustered individuals and can be related to a global reproduction number, that overrides the classical, local reproduction number.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:NoneAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are available on demand ot the authors.